Effect of autograft/allograft combination of bone marrow stem cells and Schwann cells on complete chronic and subacute spinal cord injuries.
Phase 2
Completed
- Conditions
- Cronic and subacute spinal cord injuries.Injury of spinal cord, level unspecifiedT09.3
- Registration Number
- IRCT20200502047277N8
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Age between 18 and 60
Root lesion less than three levels
Complete spinal cord injury (class A in ASIA scale)
The patient who fills informed consent
Exclusion Criteria
Systemic diseases like diabetes, Cancer, Advanced neuropathy, Myopathy, Neuromuscular disorder, etc.
Epilepsy
Concurrent lesions of peripheral nerve including traumatic lesion
Amputation
Brain damage
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the therapeutic effects of bone marrow stem cells and Schwann cells in spinal cord injury repair?
How does autograft versus allograft transplantation of bone marrow stem cells and Schwann cells compare in efficacy for complete chronic and subacute spinal cord injuries?
Which biomarkers are associated with successful outcomes following stem cell and Schwann cell transplantation in spinal cord injury patients?
What are the potential adverse events and safety management strategies for combined stem cell and Schwann cell therapies in spinal cord injury treatment?
Are there any combination approaches or competitor drugs targeting neuroregeneration in chronic and subacute spinal cord injuries, and how do they compare to the IRCT20200502047277N8 trial intervention?